Peer-reviewed Journal Details Moderna COVID-19 Vaccine Effectiveness in Phase 3 Study

The mRNA-1273 COVID-19 vaccine co-developed by biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases, part of the NIH, was 94.1% effective at preventing symptomatic coronavirus disease 2019 (COVID-19), according to a new peer-reviewed analysis of Phase 3 clinical trial data published in the New England Journal of Medicine. Additionally, the vaccine demonstrated efficacy at preventing severe COVID-19 and raised no safety concerns. The Food and Drug Administration issued an Emergency Use Authorization on Dec. 18, 2020, allowing Moderna to make the mRNA-1273 COVID-19 vaccine available for the prevention of COVID-19 in adults in the United States.  The new NEJM paper details specific findings from the Phase 3 study noting that additional analyses are underway to evaluate the vaccine's impact on SARS-CoV-2 transmission.  For more information about the NEJM paper, see: https://www.nejm.org/doi/full/10.1056/NEJMoa2035389.  Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107